ReviewWorld journal of microbiology & biotechnology2026
Quorum-quenching enzymes as next-generation antibiofilm therapeutics: mechanisms, applications, and future perspectives.
Review in World journal of microbiology & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quorum sensing (QS) is a form of cell-to-cell communication in bacteria which regulates the activities of biofilm formation, virulence, motility, sporulation and antimicrobial resistance. The growing prevalence of multidrug-resistant pathogens complicates the use of traditional antibiotics. Quorum quenching (QQ) enzymes are considered promising anti-virulence molecules that disrupt bacterial communication without any effect on cell viability. The present review is intended to offer a detailed discussion on QQ enzymes in terms of their modes of action, classification, therapeutic applications and existing challenges towards the treatment of bacterial infections. This includes QS circuits of Gram-positive and Gram-negative bacteria such as LuxI/LuxR, Las/Rhl, Agr and AI-2 systems as well as the structure, catalytic actions and substrates of QQ enzymes like AHL lactonases, acylases, oxidoreductases, paraoxonases and peptide-degrading proteases. In addition to this, some recent developments in biomedical and industrial fields involving QQ enzymes for application in biofilm control, antivirulence treatment, agriculture, aquaculture, water decontamination, coating of medical devices and nanobiotechnology are discussed. Novel drug strategies involving phage-based QQ enzymes, nanostructures, genetically modified bacteria, and the synergy between QQ and antibiotics are explained in detail for the treatment of bacteria-related diseases. In conclusion, QQ enzymes represent a promising and sustainable approach to controls bacterial pathogenicity and biofilm-associated infections.
Indexed as
Identifiers
42658376What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.